Rare Tumors: Opportunities and challenges from the Children's Oncology Group perspective.

Children’s Oncology Group adrenocortical carcinoma nasopharyngeal carcinoma pleuropulmonary blastoma rare cancer rare tumor retinoblastoma

Journal

EJC paediatric oncology
ISSN: 2772-610X
Titre abrégé: EJC Paediatr Oncol
Pays: Netherlands
ID NLM: 9918681488306676

Informations de publication

Date de publication:
Dec 2023
Historique:
medline: 13 10 2023
pubmed: 13 10 2023
entrez: 13 10 2023
Statut: ppublish

Résumé

While all childhood cancers are rare, tumors that are particularly infrequent or underrepresented within pediatrics are studied under the umbrella of the Children's Oncology Group Rare Tumor committee, divided into the Retinoblastoma and Infrequent Tumor subcommittees. The Infrequent Tumor subcommittee has traditionally included an emphasis on globally rare tumors such as adrenocortical carcinoma, nasopharyngeal carcinoma, or those tumors that are rare in young children, despite being common in adolescents and young adults, such as colorectal carcinoma, thyroid carcinoma, and melanoma. Pleuropulmonary blastoma, gonadal stromal tumors, pancreatic tumors including pancreatoblastoma, gastrointestinal stromal tumor, nonmelanoma skin cancers, neuroendocrine tumors, and desmoplastic small round cell tumors, as well as other carcinomas are also included under the heading of the Children's Oncology Group Rare Tumor committee. While substantial challenges exist in rare cancers, inclusion and global collaboration remain key priorities to ensure high quality research to advance care.

Identifiants

pubmed: 37829670
doi: 10.1016/j.ejcped.2023.100024
pmc: PMC10566015
mid: NIHMS1933059
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : K08 CA232344
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA244940
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180886
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180899
Pays : United States

Déclaration de conflit d'intérêts

Conflicts of interest: Samara Potter reports a relationship with Bayer Healthcare that includes: consulting or advisory. Theodore Laetsch reports a relationship with Advanced Microbubbles that includes: consulting or advisory. Theodore Laetsch reports a relationship with AI Therapeutics that includes: consulting or advisory. Theodore Laetsch reports a relationship with Bayer that includes: consulting or advisory. Theodore Laetsch reports a relationship with GentiBio that includes: consulting or advisory. Theodore Laetsch reports a relationship with Jazz Pharmaceuticals that includes: consulting or advisory. Theodore Laetsch reports a relationship with MassiveBio that includes:. Theodore Laetsch reports a relationship with Menarini that includes: consulting or advisory. Theodore Laetsch reports a relationship with Novartis that includes: consulting or advisory. Theodore Laetsch reports a relationship with Pyramid Biosciences that includes: consulting or advisory. Theodore Laetsch reports a relationship with Treeline Biosciences, Inc. that includes: consulting or advisory. The remaining authors have no conflicts of interest to disclose.

Références

Lancet Oncol. 2018 May;19(5):705-714
pubmed: 29606586
Cancer. 2012 Oct 1;118(19):4892-900
pubmed: 22359313
J Clin Oncol. 2019 Dec 10;37(35):3369-3376
pubmed: 31553639
Thyroid. 2015 Jul;25(7):716-59
pubmed: 25900731
Endocr Connect. 2022 Nov 17;11(12):
pubmed: 36240044
Am J Clin Pathol. 1994 May;101(5):625-9
pubmed: 8178770
Am J Hum Genet. 1999 Oct;65(4):995-1006
pubmed: 10486318
Clin Cancer Res. 2018 May 15;24(10):2251-2261
pubmed: 29343557
J Clin Oncol. 2004 Mar 1;22(5):838-45
pubmed: 14990639
Clin Cancer Res. 2017 Jun 1;23(11):e38-e45
pubmed: 28572266
JAMA Otolaryngol Head Neck Surg. 2019 Jul 1;145(7):617-623
pubmed: 31120475
J Clin Oncol. 2010 Nov 20;28(33):5011-6
pubmed: 20956621
J Natl Cancer Inst. 1994 Nov 16;86(22):1707-10
pubmed: 7966399
J Clin Endocrinol Metab. 2020 May 1;105(5):
pubmed: 31900481
Histopathology. 2022 Jan;80(1):122-134
pubmed: 34958498
Cancer. 1993 Dec 1;72(11):3145-55
pubmed: 8242539
Cancer. 2023 Feb 15;129(4):600-613
pubmed: 36541021
Cancer. 2008 Jan 15;112(2):416-32
pubmed: 18074355
J Pediatr Surg. 2013 Nov;48(11):2207-13
pubmed: 24210187
Clin Cancer Res. 2017 Jul 1;23(13):e98-e106
pubmed: 28674118
J Clin Oncol. 2020 Jan 1;38(1):71-80
pubmed: 31644329
J Clin Oncol. 2022 Nov 20;40(33):3839-3847
pubmed: 35820112
J Clin Oncol. 2023 Feb 1;41(4):778-789
pubmed: 36137255
Arch Pathol Lab Med. 2015 Oct;139(10):1263-70
pubmed: 26414472
Pediatrics. 2013 May;131(5):846-54
pubmed: 23589817
J Clin Oncol. 2021 Aug 1;39(22):2463-2473
pubmed: 33822640
Thyroid. 2020 Dec;30(12):1771-1780
pubmed: 32495721
J Clin Oncol. 2015 Feb 20;33(6):602-9
pubmed: 25584008
Klin Padiatr. 2016 Apr;228(3):105-12
pubmed: 27135270
J Clin Oncol. 2019 Nov 1;37(31):2883-2891
pubmed: 31539297
Dermatol Clin. 2013 Oct;31(4):589-98, viii
pubmed: 24075547
J Pediatr Surg. 2016 Jul;51(7):1061-6
pubmed: 26703433

Auteurs

Kris Ann P Schultz (KAP)

Cancer and Blood Disorders, Children's Minnesota, Minneapolis, MN.

Murali Chintagumpala (M)

Division of Hematology-Oncology, Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX.

Jin Piao (J)

University of Southern California Keck School of Medicine, Los Angeles, CA.

Kenneth S Chen (KS)

Department of Pediatrics, UT Southwestern Medical Center, Dallas, TX.

Rachana Shah (R)

University of Southern California Keck School of Medicine, Los Angeles, CA.
Division of Hematology-Oncology, Department of Pediatrics, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA.

Robyn D Gartrell (RD)

Division of Pediatric Hematology/Oncology, Department of Pediatrics, Columbia University Irving Medical Center, New York, NY.

Emily Christison-Lagay (E)

Yale School of Medicine, Yale New-Haven Children's Hospital, New Haven, CT.

Farzana Pashnakar (F)

Department of Pediatrics, Yale University School of Medicine, New Haven, CT.

Jesse L Berry (JL)

University of Southern California Keck School of Medicine, Los Angeles, CA.
The Vision Center, Children's Hospital Los Angeles, The Saban Research Institute, Children's Hospital Los Angeles, USC Roski Eye Institute, Norris Comprehensive Cancer Center, Los Angeles, CA.

Allison F O'Neill (AF)

Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Department of Pediatric Oncology, Boston, MA.

Lauren M Vasta (LM)

Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD.

Ashley Flynn (A)

Hematology/Oncology, Children's Mercy Kansas City, Kansas City, MO.

Sarah G Mitchell (SG)

Aflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA.
Department of Pediatrics, Emory University, Atlanta, GA.

Brittani Kn Seynnaeve (BK)

Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Jeremy Rosenblum (J)

Department of Pediatrics, Division of Pediatric Hematology/Oncology, Westchester Medical Center, New York Medical College, Valhalla, New York, NY.

Samara L Potter (SL)

The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH.
Department of Pediatrics, The Ohio State University, Columbus, OH.

Junne Kamihara (J)

Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Department of Pediatric Oncology, Boston, MA.

Carlos Rodriguez-Galindo (C)

Departments of Global Pediatric Medicine and Oncology, St. Jude Children's Research Hospital, Memphis, TN.

Douglas S Hawkins (DS)

Division of Hematology-Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA.

Theodore W Laetsch (TW)

Division of Oncology, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA.

Classifications MeSH